Physician profile
William E Houck
NPI 1265520282
$1,031.16
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $218 · 2022: $15.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $161.63 | 2019-2022 | |
| Hologic Sales and Service, LLC | $160.48 | 2019 | |
| Merck Sharp & Dohme LLC | $117.83 | 2019 | |
| Pfizer INC. | $116.63 | 2019-2020 | |
| Covidien LP | $63.31 | 2019-2020 | |
| Amgen INC. | $56.39 | 2019-2020 | |
| Aesculap, INC. | $55.41 | 2019-2020 | |
| Therapeuticsmd, INC. | $44.06 | 2020 | |
| Lupin INC. | $39.92 | 2019-2020 | |
| Astellas Pharma US INC | $34.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.27 | 2019 | |
| Duchesnay USA Incorporated | $29.50 | 2019 | |
| Daiichi Sankyo INC. | $18.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.33 | 2020 | |
| Ethicon US, LLC | $17.60 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $13.70 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.12 | 2020 | |
| Boston Scientific Corporation | $12.85 | 2019 | |
| Exeltis, USA INC. | $12.14 | 2020 | |
| Smith+Nephew, INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Houck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.